E Charbek1, K Huynh, E Kim, R P Nayak. 1. Edward Charbek, Saint Louis University, St. Louis, MO, USA, Email Address: edward.charbek@health.slu.edu.
Abstract
OBJECTIVES: To determine the prevalence of cognitive impairment in chronic obstructive pulmonary disease (COPD) patients using the Rapid Cognitive Screen (RCS). DESIGN: Cross sectional study. PARTICIPANTS: A total of 106 men and women with COPD 50 years of age or older. SETTING: Pulmonary ambulatory clinic in a tertiary academic center in St. Louis, Missouri, USA. MEASUREMENTS: We enrolled patients with COPD who completed the RCS tool. Patients were classified as having normal cognition, mild cognitive impairment (MCI), or dementia if they scored ≥ 8, 6-7, or ≤ 5, respectively. The prevalence of each category was measured, and patients' baseline characteristics were compared. RESULTS: One hundred and six patients completed the RCS. Of those, 36 (33.9%) patients scored ≤ 5 on the RCS, 33 (31.1%) scored 6 or 7, and 37 (34.9%) scored ≥ 8. The prevalence of dementia, MCI, and normal cognition were 33.9%, 31.1%, and 34.9%, respectively. Baseline lung function was not different between patients with normal cognition and those with abnormal cognition (FEV1 1.53 ± 0.39 vs 1.45 ± 0.32 L). In patients with abnormal cognition, there was no difference in patients' characteristics between patients with MCI or dementia. CONCLUSION: Cognitive impairment is highly prevalent in patients with COPD. RCS successfully identified cognitive impairment in COPD. We recommend performing RCS in patients with COPD routinely.
OBJECTIVES: To determine the prevalence of cognitive impairment in chronic obstructive pulmonary disease (COPD) patients using the Rapid Cognitive Screen (RCS). DESIGN: Cross sectional study. PARTICIPANTS: A total of 106 men and women with COPD 50 years of age or older. SETTING: Pulmonary ambulatory clinic in a tertiary academic center in St. Louis, Missouri, USA. MEASUREMENTS: We enrolled patients with COPD who completed the RCS tool. Patients were classified as having normal cognition, mild cognitive impairment (MCI), or dementia if they scored ≥ 8, 6-7, or ≤ 5, respectively. The prevalence of each category was measured, and patients' baseline characteristics were compared. RESULTS: One hundred and six patients completed the RCS. Of those, 36 (33.9%) patients scored ≤ 5 on the RCS, 33 (31.1%) scored 6 or 7, and 37 (34.9%) scored ≥ 8. The prevalence of dementia, MCI, and normal cognition were 33.9%, 31.1%, and 34.9%, respectively. Baseline lung function was not different between patients with normal cognition and those with abnormal cognition (FEV1 1.53 ± 0.39 vs 1.45 ± 0.32 L). In patients with abnormal cognition, there was no difference in patients' characteristics between patients with MCI or dementia. CONCLUSION:Cognitive impairment is highly prevalent in patients with COPD. RCS successfully identified cognitive impairment in COPD. We recommend performing RCS in patients with COPD routinely.
Authors: Bartolome R Celli; Marc Decramer; Jadwiga A Wedzicha; Kevin C Wilson; Alvar A Agustí; Gerard J Criner; William MacNee; Barry J Make; Stephen I Rennard; Robert A Stockley; Claus Vogelmeier; Antonio Anzueto; David H Au; Peter J Barnes; Pierre-Regis Burgel; Peter M Calverley; Ciro Casanova; Enrico M Clini; Christopher B Cooper; Harvey O Coxson; Daniel J Dusser; Leonardo M Fabbri; Bonnie Fahy; Gary T Ferguson; Andrew Fisher; Monica J Fletcher; Maurice Hayot; John R Hurst; Paul W Jones; Donald A Mahler; François Maltais; David M Mannino; Fernando J Martinez; Marc Miravitlles; Paula M Meek; Alberto Papi; Klaus F Rabe; Nicolas Roche; Frank C Sciurba; Sanjay Sethi; Nikos Siafakas; Don D Sin; Joan B Soriano; James K Stoller; Donald P Tashkin; Thierry Troosters; Geert M Verleden; Johny Verschakelen; Jorgen Vestbo; John W Walsh; George R Washko; Robert A Wise; Emiel F M Wouters; Richard L ZuWallack Journal: Eur Respir Rev Date: 2015-06
Authors: Balwinder Singh; Ajay K Parsaik; Michelle M Mielke; Rosebud O Roberts; Paul D Scanlon; Yonas E Geda; V Shane Pankratz; Teresa Christianson; Barbara P Yawn; Ronald C Petersen Journal: Mayo Clin Proc Date: 2013-11 Impact factor: 7.616